Darren E Stewart
First author of the 2026 GeroScience registry study of rapamycin and survival in kidney transplant recipients.
NYU Langone Health, New York
Darren E Stewart is first author of STE2026, a registry cohort of 11,474 kidney transplant recipients who were alive with a working graft at one year. After weighting for age, BMI, diabetes and other factors, median survival age was 64.6 years with rapamycin and 64.3 years without, so the study did not see a clear survival gain from mTOR inhibition.
In PubMed he is listed in the Department of Surgery at NYU Langone Health.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Rapamycin and human longevity among kidney transplant recipients surviving the first year. STE2026 First author. Registry data show no clear survival difference with rapamycin in kidney transplant recipients. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Darren E Stewart.
ShowHide
- William E Fitzsimmons Last and corresponding author of the 2026 GeroScience registry study of rapamycin and survival in kidney transplant recipients.
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.